Brightline-1: When a Negative Trial Reveals Two Active Therapies
Open Access
- 14 August 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4511-4513
Abstract
Summary: Although Brightline-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with the median PFS of 8.4 months, objective response rate of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in dedifferentiated liposarcoma. See related article by Schöffski et al., p. 4538Keywords
This publication has 5 references indexed in Scilit:
- Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III TrialClinical Cancer Research, 2026
- SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Journal of Clinical Oncology, 2026
- The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation StudyCancer Discovery, 2023
- A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or LymphomasJournal of Clinical Oncology, 2023
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013